All in on nov­el tar­get GSK-3β, Ac­tu­ate Ther­a­peu­tics rais­es $21M+ to bankroll am­bi­tious PhI/II

7 years ago
Financing

Four years af­ter EU ap­proval, NICE fi­nal­ly backs Revlim­id use in cer­tain first-line mul­ti­ple myelo­ma pa­tients

7 years ago
Pharma

Ab­b­Vie/Roche's Ven­clex­ta wins fourth ap­proval; WuXi, fel­low CRO Al­ta­sciences ink deal

7 years ago
News Briefing

Can a lit­tle known drug in As­traZeneca's pipeline make a come­back as a PARP add-on? Yale sci­en­tists ex­plain how

7 years ago
Discovery

Af­ter a long march with Cabo, Ex­elix­is is ex­pand­ing its fo­cus with an an­ti­body-drug con­ju­gate deal

7 years ago
R&D
Pharma

Genen­tech lines up a new au­toim­mune R&D al­liance on a 'po­ten­tial­ly trans­for­ma­tive' tech

7 years ago
R&D
Discovery

An­a­lysts spot­light the win­ners — and losers — on AS­CO pre­view night

7 years ago
R&D
Pharma

As Dai­ichi Sankyo-part­nered breast can­cer drug march­es to­ward fin­ish line, As­traZeneca brings in Cana­di­an sci­en­tist ...

7 years ago
People

Gink­go BioWorks picks up an­tibi­otics ef­fort with Roche where Warp Dri­ve Bio left off

7 years ago
R&D

Can we stop can­cer cells from evolv­ing and de­vel­op­ing drug re­sis­tance? British sci­en­tists take a leaf out of the HIV ...

7 years ago
Discovery

Iso­Plex­is bags $25M to stoke T cell ther­a­py buzz; Col­lab­o­ra­tion be­tween X4 and LLS; New CMO at Pre­ci­sion Bio­sciences

7 years ago
News Briefing

J&J pol­ish­es up its new list of late-stage block­buster can­di­dates — and can­cer re­mains big

7 years ago
R&D
Pharma

Im­muno­Gen shares tank (again) af­ter the FDA nix­es a shot at an OK for its armed an­ti­body in wake of a failed PhI­II

7 years ago
R&D
Pharma

Pfiz­er jumps in­to the heat­ed PhI­II race for new-wave JAK in­hibitors — but safe­ty frets loom large

7 years ago
R&D

Ver­tex wa­gers $70M on Kymera and its new fas­ci­na­tion with pro­tein degra­da­tion

7 years ago
R&D

A top ex­ec at strug­gling Bio­gen jumps ship for a new job

7 years ago
R&D

Pfiz­er, Mer­ck KGaA clinch need­ed ap­proval for Baven­cio, di­rect­ly com­pet­ing against Keytru­da in kid­ney can­cer

7 years ago
Pharma

Al­most half of all new drug ap­provals in 2018 re­lied on one clin­i­cal tri­al

7 years ago
Pharma
FDA+

No­var­tis takes an­oth­er step for­ward in glob­al Kym­ri­ah roll­out as Japan OKs the drug at $305K

7 years ago
R&D

Dai­ichi Sankyo 'dis­ap­point­ed' as FDA ex­perts spurn AML drug but vote in fa­vor of rare tu­mor drug

7 years ago
R&D

Take­da fore­casts $1.7B loss af­ter Shire in­te­gra­tion; Flag­ship's pre­clin­i­cal biotech Ax­cel­la clos­es IPO with $71M+ ...

7 years ago
News Briefing

My­ovan­t's re­l­u­golix clears first uter­ine fi­broids PhI­II test, but com­pe­ti­tion from Ab­b­Vie/Neu­ro­crine makes in­vestors ...

7 years ago
R&D

Re­jig­ging Mer­ck KGaA part­ner­ship, Eliot Forster gains full con­trol of the al­pha in F-star's con­stel­la­tion

7 years ago
R&D

Boehringer In­gel­heim flies the white flag as last hold­out sur­ren­ders in war over a $20B Ab­b­Vie gold mine

7 years ago
Pharma
First page Previous page 949950951952953954955 Next page Last page
A service from the Financial Times